Life Technologies | LIFE - Cash And Equivalent



Life Technologies reported $17.22M in Cash and Equivalent for its fiscal quarter ending in June of 2025.


Cash And Equivalent Change Date
Ardelyx USD 90.04M 41.39M Jun/2025
Biogen USD 2.76B 160.5M Jun/2025
Bristol-Myers Squibb USD 12.6B 1.72B Jun/2025
Cipla INR 8B 1.22B Mar/2025
Clal Biotechnology ILS 5.73M 1.71M Dec/2023
Compugen USD 6.47M 11.76M Jun/2025
CSL 1.52B 133M Dec/2024
Galapagos EUR 108.07M 43.83M Mar/2025
GlaxoSmithKline GBP 3.6B 865M Jun/2025
Grifols EUR 979.78M 334.84M Dec/2024
Life Technologies USD 17.22M 6.16M Jun/2025
Novartis USD 6.66B 410M Jun/2025
Roche Holding CHF 6.98B 2.15B Dec/2024
United Therapeutics USD 1.59B 306.8M Jun/2025